Evogene Ltd. (NASDAQ:EVGN) Sees Significant Growth in Short Interest

Evogene Ltd. (NASDAQ:EVGN) was the target of a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 135,100 shares, an increase of 503.1% from the October 31st total of 22,400 shares. Approximately 2.6% of the shares of the company are short sold. Based on an average trading volume of 272,900 shares, the short-interest ratio is currently 0.5 days.

Evogene Stock Up 3.1 %

EVGN stock traded up $0.05 during trading on Wednesday, hitting $1.67. The company had a trading volume of 63,501 shares, compared to its average volume of 89,250. The stock has a market cap of $8.97 million, a price-to-earnings ratio of -0.36 and a beta of 1.43. The firm has a 50-day moving average price of $2.32 and a 200-day moving average price of $4.33. Evogene has a 12 month low of $1.44 and a 12 month high of $10.40.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on EVGN shares. Lake Street Capital lowered their price objective on Evogene from $30.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, August 23rd. StockNews.com initiated coverage on shares of Evogene in a report on Tuesday. They issued a “sell” rating on the stock.

Institutional Investors Weigh In On Evogene

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC bought a new stake in Evogene Ltd. (NASDAQ:EVGN) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is currently owned by institutional investors.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.